Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 165

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 8
Chunk 165
---
683 $1.81 

43

Table of Contents

Quarterly Results and Business Overview 

The following section describes our net sales and results of operations by reportable segment and business. For additional information on our businesses and product offerings, refer to Item 1. Business of our most recent Annual Report on Form 10-K. 

 Three Months Ended September 30,(in millions)20252024Increase/(Decrease)Endoscopy$747 $678 10.1%Urology682 532 28.1%Neuromodulation293 268 9.1%MedSurg1,722 1,479 16.4%Cardiology2,641 2,129 24.0%Peripheral Interventions702 602 16.7%Cardiovascular3,343 2,731 22.4%Net Sales$5,065 $4,209 20.3%Nine Months Ended September 30,(in millions)20252024Increase/(Decrease)Endoscopy$2,157 $1,996 8.0%Urology1,992 1,570 26.9%Neuromodulation866 807 7.4%MedSurg5,015 4,373 14.7%Cardiology7,717 6,048 27.6%Peripheral Interventions2,056 1,765 16.5%Cardiovascular9,773 7,813 25.1%Net Sales$14,788 $12,186 21.4%

MedSurg

Endoscopy 

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) conditions with innovative, less-invasive technologies. Net sales of Endoscopy products of $747 million during the third quarter and $2.157 billion during the first nine months of 2025 represented 15 percent of our consolidated net sales in both periods. Endoscopy net sales increased $69 million, or 10.1 percent, during the third quarter and $160 million, or 8.0 percent, during the first nine months of 2025, compared to the prior year periods. During the third quarter of 2025, this increase included operational net sales growth of 9.0 percent and the positive impact of 110 basis points from foreign currency fluctuations, compared to the prior year period. During the